Navigation Links
Cardium Reports on First Quarter 2008 Highlights and Financial Results
Date:5/9/2008

y of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, and our ability to obtain necessary funding, regulatory approvals and expected qualifications, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such devices and launch new devices will be successful or completed within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Excha
'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008).../- Informed Medical Communications,(I...rums for the,bio-pharmaceutical industry, today an...e President, Marketing. In this role, Stoogenke wi...Peer Group, RxDialogue and,IMC with the objective ...the industry., (Logo: http://www.newscom.com/cgi...
(Date:5/12/2008)...y,s commitment to the community and its biotech ...IS, May 12 /- Eli Lilly and...of the final phase of its $1 billion,effort to fur...ch and,development capabilities., At a ceremony a...ong,with participation by Indianapolis Mayor Grego...
(Date:5/12/2008)...ay 12 /- Nektar,Therapeutic...rietary,PEGylation technology is used in the novel...ased erythropoiesis-stimulating agent that is unde...ent Center, Inc. and,Affymax. Data were presented ...ss in Stockholm, Sweden, which showed that Hematid...
(Date:5/12/2008)...Poised to Impact Lung Cancer Care, ST. LOUIS, May...medical,device start-up company, has secured $4.75...e adoption of its IG4 delivery system for minimall...s-based Prolog Ventures led,the round and was join...ate,investors. Veran also relocated its headquarte...
Breaking Biology Technology:Informed Medical Communications Hires New Vice President of Marketing 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 3Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress 2Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress 3Veran Medical Technologies Secures $4.75M in First Institutional Funding 2
..., , , , Jochen Meier, Ivonne Str...arie Grantyn , Developmental Physiology, J... Medical School (Charit), Berlin, Germany , ... neuronal cell cultures is of critical , im...lar basis of neuronal , physiology. Here, w...
..., , , , For automated purification o...e blood* , , , , ... samples in increments , of 8), ... , Sample sources: , ...ulants , such as citrate and EDTA) ,...
..., , , , For fast and efficient mul..., , , , Kit ... Storage and Stability , ...ormation , Product Use Limitations ... Guarantee , Introduction , ...
..., , , , QIAGEN Instrument Service a... , to guarantee you optimal performance in ...N Instrument Service provides customized agreement...rom small-scale research and general liquid-handli...mation systems for functional genomics, , g...
Other Biology Technology:Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 2Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 3Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 4QIAamp DNA Blood BioRobot MDx Kit 2QIAGEN Multiplex PCR Handbook 2QIAGEN Multiplex PCR Handbook 3QIAGEN Multiplex PCR Handbook 4QIAGEN Multiplex PCR Handbook 5QIAGEN Multiplex PCR Handbook 6QIAGEN Multiplex PCR Handbook 7QIAGEN Multiplex PCR Handbook 8QIAGEN Multiplex PCR Handbook 9QIAGEN Multiplex PCR Handbook 10QIAGEN Multiplex PCR Handbook 11QIAGEN Multiplex PCR Handbook 12QIAGEN Multiplex PCR Handbook 13QIAGEN Multiplex PCR Handbook 14QIAGEN Multiplex PCR Handbook 15QIAGEN Multiplex PCR Handbook 16QIAGEN Multiplex PCR Handbook 17QIAGEN Multiplex PCR Handbook 18QIAGEN Multiplex PCR Handbook 19QIAGEN Multiplex PCR Handbook 20QIAGEN Multiplex PCR Handbook 21QIAGEN Multiplex PCR Handbook 22QIAGEN Multiplex PCR Handbook 23QIAGEN Multiplex PCR Handbook 24QIAGEN Multiplex PCR Handbook 25QIAGEN Multiplex PCR Handbook 26QIAGEN Multiplex PCR Handbook 27QIAGEN Multiplex PCR Handbook 28QIAGEN Multiplex PCR Handbook 29QIAGEN Multiplex PCR Handbook 30QIAGEN Multiplex PCR Handbook 31QIAGEN Multiplex PCR Handbook 32
(Date:5/9/2008)... Highlights: , Mechanism of action of compound ... cells , The findings may lead researchers to de...,s disease, amyotrophic lateral sclerosis, Hunting...and malignant gliomas , RICHMOND, Va. (May 9, 2... have discovered how an antibiotic works to modula...
(Date:5/9/2008)...E, Calif. - The radioactive carbon-14 produced by ... has helped researchers determine that the number ...ese, is established during the teenage years. Chan...nly to changes in fat cell volume, not an increase...lts could help researchers develop new pharmaceuti...
(Date:5/9/2008)...national group of scientists has swapped their com...environments on the planet to carry out a challeng...ring the data delivered by ESA,s ice mission CryoS...ists, mainly from Denmark, UK, Germany and Canada,... Experiment (CryoVEx) 2008, an extensive three-wee...
(Date:5/8/2008)...ASSEE, Fla. -- Now that the genome (DNA) of humans...logists are turning their attention to discovering...genes -- the worker bees of living cells that can ... they need to develop new techniques and tools. Sc...tional High Magnetic Field Laboratory at Florida S...
Breaking Biology News(10 mins):Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 2Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 3New technique determines the number of fat cells remains constant in all body types 2New technique determines the number of fat cells remains constant in all body types 3Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3Magnet Lab researchers make observing cell functions easier 2Cell Therapeutics Inc 28CTI 29 Cuts Net Operating Expenses 35 25 and Expands Commercial Team to Support Zevalin 28R 29 Sales and Applications Seeki 10565 1Cell Therapeutics Inc 28CTI 29 Cuts Net Operating Expenses 35 25 and Expands Commercial Team to Support Zevalin 28R 29 Sales and Applications Seeki 10565 2Cell Therapeutics Inc 28CTI 29 Cuts Net Operating Expenses 35 25 and Expands Commercial Team to Support Zevalin 28R 29 Sales and Applications Seeki 10565 3Cell Therapeutics Inc 28CTI 29 Cuts Net Operating Expenses 35 25 and Expands Commercial Team to Support Zevalin 28R 29 Sales and Applications Seeki 10565 4Cell Therapeutics Inc 28CTI 29 Cuts Net Operating Expenses 35 25 and Expands Commercial Team to Support Zevalin 28R 29 Sales and Applications Seeki 10565 575 Percent of Virginia Voters Support Smoke Free Workplaces 10563 175 Percent of Virginia Voters Support Smoke Free Workplaces 10563 275 Percent of Virginia Voters Support Smoke Free Workplaces 10563 3First Pharmaceutical Company Comes to Hoboken NJ 3A Swiss Based Octapharma to Move U S Headquarters to SJP Properties Waterfront Corporate Center II 10561 1First Pharmaceutical Company Comes to Hoboken NJ 3A Swiss Based Octapharma to Move U S Headquarters to SJP Properties Waterfront Corporate Center II 10561 2First Pharmaceutical Company Comes to Hoboken NJ 3A Swiss Based Octapharma to Move U S Headquarters to SJP Properties Waterfront Corporate Center II 10561 3First Pharmaceutical Company Comes to Hoboken NJ 3A Swiss Based Octapharma to Move U S Headquarters to SJP Properties Waterfront Corporate Center II 10561 4Journal of Opioid Management Welcomes New Editor in Chief 21 10559 1Journal of Opioid Management Welcomes New Editor in Chief 21 10559 2
...nservation assessments of endangered Caribbean sea...Clenachan and colleagues from the Scripps Institut...and Marah Newman agree that conservation efforts s...green and hawksbill turtle populations that nest o...ndling turtle populations on many historically imp...
...t decade, the oyster population in New Hampshire,s...e to the 1995 arrival of the oyster disease MSX. T...tating demise of oysters from exuberant overharves...," says Ray Grizzle, research associate professor ...rine Laboratory. , Now Grizzle is working to brin...
... at Joslin Diabetes Center have discovered that a ... diabetes (insulin-dependent) who have had the dis... may still have residual functioning, insulin-prod...e findings will be presented June 12 at the Americ...ic Sessions in Washington, D.C. , "It is surprisi...
...at Washington University in St. Louis has develope...pel pests , sweeten the air, and some day might ev...asal spray, for instance. , Karen L. Wooley, Ph.D...nguished University Professor in Arts & Scienc...ed more than four years ago as marine "antifouling...
Other Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3Triple threat polymer captures and releases 2Triple threat polymer captures and releases 3Triple threat polymer captures and releases 4
G-protein coupled purinergic receptor P2Y8
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller.
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors.
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144
Biology Products: